#Alkermes

pharmaphorum

@pharmaphorum.bsky.social

2 weeks ago

Changes at the top of Sarepta, Alkermes, as CEOs depart Two long-serving pharma CEOs have announced their departures, as Sarepta's Doug Ingram and Alkermes' Richard Pops announce their retirement.

Two long-serving #pharmachiefexecutives have announced their departures, as #DougIngram steps down from #Sarepta and #RichardPops plans his #retirement from #Alkermes.

pharmaphorum.com/news/changes...

GLOBAL Visibility aéPiot - by aePiot.ro

@globalvisibility.bsky.social

2 months ago

#ICE #DISAMBIGUATION
multi-search-tag-explorer.headlines-world.com/advanced-sea...
#ALKERMES #PLC
multi-search-tag-explorer.aepiot.com/advanced-sea...
#PLUTONIUM #TRIOXIDE
headlines-world.com/advanced-sea...
headlines-world.com

pharmaphorum

@pharmaphorum.bsky.social

3 months ago

Lundbeck bows out of bidding war for Avadel Lundbeck won't raise its offer to buy Avadel any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes.

#Lundbeck has said it won't raise its offer to buy #AvadelPharma any further, clearing the way for the sleep disorder specialist to complete a #merger with #Alkermes.

pharmaphorum.com/news/lundbec...

pharmaphorum

@pharmaphorum.bsky.social

3 months ago

Alkermes offers more for Avadel after Lundbeck bid Alkermes has been forced to raise its offer for narcolepsy drug developer Avadel Pharma, after a rival bid from Lundbeck was deemed superior.

#Alkermes has been forced to raise its offer for #narcolepsy drug developer #AvadelPharma, after a rival bid from #Lundbeck was deemed superior.

@pharmalot.bsky.social

3 months ago

Pharmalittle: We're reading about a Novo drug and Alzheimer's, a Sarepta drug warning, and more Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a Novo drug and Alzheimer’s, a Sarepta drug warning, and more news.. statnews.com/pharmalot/20... #pharma #Alzheimers #CVS #GLP1 #opioids #Purdue #Merck #HIV #NovoNordisk #Alkermes

Thiard News@F4F

@newsen.bsky.social

3 months ago

Alkermes Increases Its Acquisition Offer for Avadel Pharmaceuticals to $22.50 Per Share Alkermes plc has raised its offer to acquire Avadel Pharmaceuticals, proposing a total value of up to $22.50 per share. This new proposal includes cash and contingent value rights.

Alkermes Increases Its Acquisition Offer for Avadel Pharmaceuticals to $22.50 Per Share #Ireland #Dublin #Alkermes #LUMRYZ #Avadel_Pharmaceuticals

pharmaphorum

@pharmaphorum.bsky.social

4 months ago

Lundbeck makes bid for Avadel, trying to displace Alkermes Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product.

Another pharma M&A fight has broken out, with #Lundbeck outbidding #Alkermes in an attempt to take control of #AvadelPharma and its approved therapy for the sleep disorder #narcolepsy.

@pharmalot.bsky.social

4 months ago

Pharmalittle: We're reading about a Merck acquisition, Novo facing shareholder backlash, and more Merck agreed to buy Cidara Therapeutics, the maker of an experimental flu therapy, in a $9.2 billion deal

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a Merck acquisition, Novo facing shareholder backlash, and more news.. statnews.com/pharmalot/20... #pharma #flu #opioids #Merck #NovoNordisk #JNJ #BristolMyers #Lundbeck #Alkermes #Cidara

Thiard News@F4F

@newsen.bsky.social

4 months ago

Alkermes Analyzes Avadel's Announcement Regarding Potential Acquisition Alkermes assesses Avadel Pharmaceuticals' recent announcement about a potential acquisition offer from H. Lundbeck A/S, revealing strategic considerations.

Alkermes Analyzes Avadel's Announcement Regarding Potential Acquisition #USA #Dublin #Lundbeck #Alkermes #Avadel

Thiard News@F4F

@newsen.bsky.social

4 months ago

Alkermes Responds to Avadel's Potential Acquisition Offer by Lundbeck Alkermes plc has acknowledged Avadel Pharmaceuticals' recent announcement concerning a potential acquisition bid from Lundbeck, evaluating its options.

Alkermes Responds to Avadel's Potential Acquisition Offer by Lundbeck #USA #Dublin #Lundbeck #Alkermes #Avadel

Thiard News@F4F

@newsen.bsky.social

4 months ago

Alkermes Reports Promising Findings from Vibrance-2 Study of Alixorexton for Narcolepsy Type 2 Alkermes has announced successful phase 2 study results for Alixorexton, marking a potential breakthrough treatment for Narcolepsy Type 2, paving the way for phase 3 trials.

Alkermes Reports Promising Findings from Vibrance-2 Study of Alixorexton for Narcolepsy Type 2 #USA #Dublin #Alkermes #Narcolepsy #Alixorexton

Thiard News@F4F

@newsen.bsky.social

4 months ago

Alkermes Reports Exciting Results for Alixorexton in Narcolepsy Type 2 Study Alkermes has unveiled promising results from the Vibrance-2 study, featuring Alixorexton for Narcolepsy Type 2, showing significant improvements in wakefulness.

Alkermes Reports Exciting Results for Alixorexton in Narcolepsy Type 2 Study #USA #Dublin #Alkermes #Narcolepsy #Alxorexton

Thiard News@F4F

@newsen.bsky.social

4 months ago

Alkermes plc Posts Impressive Financial Growth in Q3 2025 Alkermes plc has reported outstanding financial results for Q3 2025, highlighting revenue growth and strategic developments.

Alkermes plc Posts Impressive Financial Growth in Q3 2025 #Ireland #Dublin #pharmaceuticals #Q3_2025 #Alkermes

pharmaphorum

@pharmaphorum.bsky.social

4 months ago

Alkermes bets $2.1bn on Avadel and its narcolepsy drug Alkermes will buy Avadel Pharma and its fast-growing narcolepsy drug Lumryz in a deal valued at up to $2.1 billion.

#Alkermes has reached an agreement to buy #AvadelPharma in a deal valued at up to $2.1 billion, claiming rights to an FDA-approved therapy for sleep disorder #narcolepsy that has been predicted to make sales of up to $275 million this year.

pharmaphorum.com/news/alkerme...

Thiard News@F4F

@newsen.bsky.social

4 months ago

Alkermes plc to Enhance Portfolio with Avadel Pharmaceuticals Acquisition Alkermes plc has announced a definitive agreement to acquire Avadel Pharmaceuticals, enhancing its commercial offerings, particularly in sleep medicine. Expected completion is in early 2026.

Alkermes plc to Enhance Portfolio with Avadel Pharmaceuticals Acquisition #Ireland #Dublin #Alkermes #Avadel #LUMRYZ

Thiard News@F4F

@newsen.bsky.social

6 months ago

Alkermes Welcomes Joshua Reed as New Chief Financial Officer Alkermes plc has appointed Joshua Reed as its new CFO, effective September 15, 2025. Reed brings three decades of financial leadership experience, especially in biotech.

Alkermes Welcomes Joshua Reed as New Chief Financial Officer #CFO #Ireland #Dublin #Alkermes #Joshua_Reed

Thiard News@F4F

@newsen.bsky.social

6 months ago

Alkermes Launches 8th Annual Pathways Research Awards Program to Foster Neuroscience Innovation Alkermes has opened applications for the 8th Annual Pathways Research Awards, supporting innovative neuroscience research with grants up to $100,000.

Alkermes Launches 8th Annual Pathways Research Awards Program to Foster Neuroscience Innovation #Ireland #Dublin #Alkermes #Pathways_Research #Neuroscience_Awards

Thiard News@F4F

@newsen.bsky.social

6 months ago

Alkermes Unveils Promising Findings on Alixorexton at World Sleep 2025 Alkermes is set to present significant insights from the Vibrance-1 Phase 2 study on alixorexton for narcolepsy Type 1 at World Sleep 2025, along with an investor webcast discussion.

Alkermes Unveils Promising Findings on Alixorexton at World Sleep 2025 #Ireland #Dublin #Alkermes #Alixorexton #Vibrance-1

Thiard News@F4F

@newsen.bsky.social

7 months ago

Alkermes plc Releases Strong Second Quarter Financial Results for 2025 Alkermes plc announces solid financial results for the second quarter of 2025, highlighting strong revenues and positive developments in product performance.

Alkermes plc Releases Strong Second Quarter Financial Results for 2025 #Ireland #Dublin #Alkermes #VIVITROL #ARISTADA

Thiard News@F4F

@newsen.bsky.social

7 months ago

Alkermes Unveils Encouraging Results from Vibrance-1 Study of Alixorexton for Narcolepsy Type 1 Patients Alkermes announces significant findings from the Vibrance-1 study, showcasing the beneficial effects of Alixorexton in improving wakefulness and cognitive functions in Narcolepsy Type 1 patients.

Alkermes Unveils Encouraging Results from Vibrance-1 Study of Alixorexton for Narcolepsy Type 1 Patients #USA #Dublin #Alkermes #Narcolepsy #Alixorexton

Thiard News@F4F

@newsen.bsky.social

7 months ago

Alkermes Unveils Encouraging Phase 2 Results for Alixorexton as Treatment for Narcolepsy Type 1 Alkermes announces promising outcomes from its Vibrance-1 Phase 2 study on Alixorexton, indicating significant improvements in wakefulness for narcolepsy type 1 patients.

Alkermes Unveils Encouraging Phase 2 Results for Alixorexton as Treatment for Narcolepsy Type 1 #USA #Dublin #Alkermes #Narcolepsy #Alixorexton

Thiard News@F4F

@newsen.bsky.social

9 months ago

Alkermes Set to Join the 46th Annual Goldman Sachs Global Healthcare Conference Alkermes plc is participating in the 46th Annual Goldman Sachs Global Healthcare Conference, presenting insights on innovative neuroscience medicines.

Alkermes Set to Join the 46th Annual Goldman Sachs Global Healthcare Conference #Goldman_Sachs #Ireland #Dublin #Alkermes #Global_Healthcare

Thiard News@F4F

@newsen.bsky.social

9 months ago

Alkermes Presents Research on Mental Health Drugs at Major Conferences in Spring 2025 Alkermes showcased its latest findings related to mental health medications at prominent conferences during Spring 2025, spotlighting important data on LYBALVI and ARISTADA.

Alkermes Presents Research on Mental Health Drugs at Major Conferences in Spring 2025 #Ireland #Dublin #Alkermes #LYBALVI #ARISTADA

Thiard News@F4F

@newsen.bsky.social

10 months ago

Alkermes plc's Promising First Quarter 2025 Financial Results Highlight Key Developments Alkermes plc reveals positive financial outcomes for Q1 2025, showcasing strong revenues, a solid product pipeline, and strategic advancements in drug development.

Alkermes plc's Promising First Quarter 2025 Financial Results Highlight Key Developments #Ireland #Dublin #Alkermes #ALKS_2680 #VIVITROL

Thiard News@F4F

@newsen.bsky.social

10 months ago

Understanding the Treatment and Diagnosis Journeys for Alcohol Use Disorder Patients: Key Survey Insights The latest survey reveals crucial insights into the diagnosis and treatment journeys of individuals with Alcohol Use Disorder, highlighting barriers and encouraging proactive healthcare.

Understanding the Treatment and Diagnosis Journeys for Alcohol Use Disorder Patients: Key Survey Insights #United_States #Dublin #Alkermes #Alcohol_Use_Disorder #The_Harris_Poll

Thiard News@F4F

@newsen.bsky.social

11 months ago

Understanding the Complex Treatment Journeys of Schizophrenia and Bipolar I Disorder Patients A recent survey reveals the challenges faced by healthcare providers in managing treatments for schizophrenia and bipolar I disorder, emphasizing the need for better patient support.

Understanding the Complex Treatment Journeys of Schizophrenia and Bipolar I Disorder Patients #United_States #Dublin #schizophrenia #Alkermes #Bipolar_I

Thiard News@F4F

@newsen.bsky.social

1 year ago

Alkermes plc Announces Strong Financial Performance and Future Outlook for 2025 Alkermes plc has posted impressive financial results for 2024 and outlined growth expectations for 2025, including new product developments.

Alkermes plc Announces Strong Financial Performance and Future Outlook for 2025 #financial_results #Ireland #Dublin #2025_Outlook #Alkermes

@carloslarrauri.bsky.social

7 years ago

www.alkermes.com www.alkermes.com

"Through this initiative, Alkermes will award up to $1 million in grants for the development or expansion of innovative programs to support the mental health and substance use disorder communities."

Apply at: www.alkermes.com/responsibility/inspirati...

#Recovery #Alkermes